

Special Issue

Advances in Brain Tumor Diagnosis: Innovations and Emerging Technologies

Message from the Guest Editor

This Special Issue will collate cutting-edge research and comprehensive reviews focused on novel diagnostic methods for brain tumors. With the increasing application of artificial intelligence, machine learning, and advanced imaging technologies, the Special Issue aims to highlight the progress made in early detection, classification, and prognostication of brain tumors, including gliomas, meningiomas, and other neuro-oncological conditions. We invite submissions that explore the integration of deep learning, medical imaging analysis, predictive modeling, and multi-modal data fusion for precise and reliable diagnostics. Topics may include (but are not limited to) innovative AI architectures, clinical data integration, and digital pathology approaches that enhance the accuracy of diagnosis and supports clinicians in their decision making. This Special Issue aspires to provide a comprehensive overview of current advancements and offer a roadmap for future breakthroughs in brain tumor diagnostics, ultimately supporting better patient outcomes and personalized treatment pathways.

Guest Editor

Dr. Mubarak Taiwo Mustapha

Operational Research Centre in Healthcare, Department of Biomedical Engineering, Near East University, Nicosia, Cyprus

Deadline for manuscript submissions

closed (30 November 2025)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/222963

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).